Lupin launches Sevelamer Hydrochloride tablets in the United States

Sevelamer Hydrochloride tablets, 800 mg is a generic equivalent of Renagel tablets, 800 mg

Lupin announced the launch of Sevelamer Hydrochloride tablets, 800 mg, having received approval from the United States Food and Drug Administration (FDA).  The product will be manufactured at Lupin’s facility in Nagpur, India. 

Sevelamer Hydrochloride tablets, 800 mg is a generic equivalent of Renagel tablets, 800 mg of Genzyme Corporation.

Sevelamer Hydrochloride tablets, 800 mg (RLD: Renagel) had estimated annual sales of US $ 75 million in the U.S. (IQVIA MAT December 2021).